PSILORIS — Psilocybin Research and Information Standards. Evidence-graded psilocybin research education.PSILOPsilocybinRResearchIInformationSStandards

High-quality trials in cancer-related anxiety and a dedicated Phase 2 GAD program show clinically meaningful anxiolytic signals. Meta-analyses support post-acute anxiety reductions, while primary panic disorder remains understudied and is tracked separately.

Multiple modern trials and several meta-analyses show rapid and clinically meaningful antidepressant effects from psilocybin-assisted therapy in major depression and treatment-resistant depression. Durability, blinding limits, harms reporting, and supervised-setting requirements remain active research questions.

Randomised and pilot data suggest psilocybin-assisted psychotherapy can reduce heavy drinking, support smoking cessation, and — in a 2026 RCT — improve cocaine abstinence. Evidence is encouraging but indication-specific and still maturing.

Early open-label work, published case reports, and a modern Yale RCT (preprint primary results plus peer-reviewed qualitative nested analysis) show clinically meaningful OCD symptom reductions after supervised psilocybin. Larger confirmatory trials are still needed, so PSILORIS keeps OCD as a candidate indication.

Dedicated controlled trials of psilocybin for primary panic disorder are largely absent. Current material is limited to comorbid observations, public-health toxicology noting acute panic provocation risk, and theoretical mechanistic discussion.

Psilocybin is a biologically and psychologically plausible candidate for PTSD. An open-label Phase 2 COMP360 study now shows tolerability and large symptom reductions to 12 weeks, but dedicated large controlled efficacy trials still lag behind MDMA-assisted therapy research.

There are no dedicated psilocybin trials for DID. Modern protocols commonly exclude it, standard DID care centres on specialised psychotherapy rather than psychedelics, and recent theoretical work emphasises risk of dissociative destabilisation alongside speculative ideas about treating traumatic dissociation more broadly.

Current clinical consensus treats personal or strong family history of psychotic disorders as a major exclusion criterion for psilocybin therapy. Systematic reviews and case reports do not support benefit and highlight elevated risk of harm, especially with heavy or repeated unsupervised use in predisposed people.